Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects
NCT06810505Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2025
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Atogepant with Placebo for Atogepant (2 arms). Primary endpoints: Number of Participants Experiencing Adverse Events at 16 weeks and Change From Baseline in Mean Monthly Migraine Days at 12 weeks. Started Feb 2025; status: recruiting.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT06810505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810505.